Two well-defined signaling pathways in regulating angiogenesis, VEGF and Notch, were extensively investigated [47], and numerous inhibitors targeting VEGF and Notch were developed and either approved by FDA or under Phase I clinical trials for cancer treatment [48,49]. This evidence concerns the gene VEGFA and cancer.